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During cancer invasion, breakdown of the extracellular matrix is
accomplished by the concerted action of several proteases,
including the serine protease plasmin and a number of matrix
metalloproteases (MMPs). The activity of each of these proteases
is regulated by an array of activators, inhibitors and cellular
receptors. Thus, the generation of plasmin involves the pro-
enzyme plasminogen, the urokinase type plasminogen activator
uPA and its pro-enzyme pro-uPA, the uPA inhibitor PAI-1, the cell
surface uPA receptor uPAR, and the plasmin inhibitor a2-antiplas-
min. The plasminogen activation system appears to be active in
virtually all types of cancer, while various MMPs appear to be
active more selectively in different types of cancer.
Generation of extracellular proteolysis in cancer involves a
complex interplay between cancer cells and non-malignant stro-
mal cells which has far-reaching consequences for our under-
standing of both carcinogenesis and establishment of
metastases. For some types of cancer, the cellular interplay mim-
ics that observed in the tissue of origin during non-neoplastic tis-
sue remodelling processes. We propose that cancer invasion is
considered as uncontrolled tissue remodelling.
Inhibition of extracellular proteases is an attractive approach
to cancer therapy. Because the proteases have many functions
in the normal organism, efficient inhibition will have toxic side
effects. In cancer invasion, like in normal tissue remodelling
processes, there appears to be a functional overlap between dif-
ferent extracellular proteases. This redundancy means that
combinations of protease inhibitors must be used. Such combi-
nation therapy, however, is also likely to increase toxicity.
Therefore for each type of cancer, a combination of protease
inhibitors that is optimised with respect to both maximal ther-
apeutic effect and minimal toxic side effects needs to be
identified.
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uPAR is a GPI-anchored protein that signals by interacting with
extracellular matrix proteins, transmembrane tyrosine kinase
receptors, integrins and G-protein coupled receptors. uPAR regu-
lates adhesion by either direct RGD-independent binding to vitro-
nectin (VN), or by forming complexes with integrins. In this case
uPAR appears to have higher affinity for alpha5 > alpha3 >
alpham. uPAR can both activate and inactivate integrins and
induce signaling via integrins or via other receptors. A seven
trans-membrane G-protein coupled receptor, FPRL1, directly
interacts with a uPA-cleaved form of uPAR (which cannot bind
integrins) and transmits a chemokine-like signal inducing che-
motaxis. In addition, uPAR can also interact with the EGF-receptor
and induce either cell proliferation (via the ERK pathway) or cell
migration. The choice between these two effects of uPAR may
be dependent on different conformations of uPAR and hence on
different types of interactions in different cells.
An important novel feature of uPAR is its involvement in the
mobilization of hematopoietic stem cells. Indeed, uPAR Ko mice
do not mobilize HSC, but this property can be rescued by admin-
istering a soluble form of uPAR or one of its fragments, D2D3. We
have set up the tools and methodology for measuring the forma-
tion and the level of circulating D2D3 in human biological fluids
since HSC mobilization is an important aspect of leukemia and
lymphoma therapy. Indeed, the availability of a specific D2D3
assay allows the determination of the level of this fragments in
all types of cancer and hence the correlation with the stage of
the tumor.
Overexpression is one of the mechanisms transforming pro-
tooncogenes into oncogenes. In human tumors uPAR is almost
invariably overexpressed. UPAR overexpression controls cell pro-
liferation by constitutively activating integrins and growth factor
receptor pathways. However, recent data on cells carrying no
oncogenes mutation (embryonic mouse fibroblasts, MEF) have
shown that the absence of uPAR causes an increase in cell prolif-
eration rate and delays culture-induced senescence. On the other
hand, overexpression of uPAR in MEFs causes senescence. In this
type of activity, key regulatory proteins of the p53/Rb pathways
are involved.
doi:10.1016/j.ejcsup.2006.04.008
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Most patients with inoperable primary cancer, with or without
overt metastases, or patients with undetected disseminated dis-
ease undergoing surgery for their primary cancer, are not cured
by adjuvant chemotherapy. It is thought that residual tumor
cells in patients with disseminated disease might exit prolifera-
tion and activate a survival and G0/G1 arrest that allows them to
become dormant. The mechanisms that trigger and maintain
dormancy are not well understood and the assumption that
the lack of proliferation of dormant cells is the only reason
for their resistance to chemotherapy remains to be proven.
The elucidation of the molecular basis of dormancy is of funda-
mental interest. We have shown that a rapidly tumorigenic and
spontaneously metastasizing human carcinoma (T-HEp3) that is
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passaged for a prolonged period of time in culture, undergoes a
non-clonal change reflected in lower ERK activity, increased p38
activity and a dormant/quiescent phenotype in vivo (D-HEp3).
When inoculated in vivo 80% of D-HEp3 cells rapidly arrest
in G0/G1 by day 6 after inoculation and remain dormant for sev-
eral months. We also found that activated p38 establishes a neg-
ative feedback loop to ERK and that blocking of p38 by genetic
or pharmacological inhibitors restores ERK activation and inter-
rupts tumor dormancy in vivo. These studies implicated high
p38 activity in the induction of dormancy in vivo. While p38 is
known to induce growth arrest and/or apoptosis, there is also
evidence indicating that in some instances, p38 signaling can
promote cell survival. However, knowledge of the proximal tar-
gets of p38 that underlie the p38-dependent dormancy program,
in particular the balance between cell proliferation and cell
death, have not been identified. We now show that p38 regu-
lates the activation of the endoplasmic reticulum (ER)-stress
activated kinase PERK and expression of the ER chaperone BiP/
Grp78. Regulation by p38 of these pathways allows dormant
tumor cells to not only become dormant but also resist drug-
toxicity. Increased activation of the eIF2a kinase PERK, results
in upregulation of ATF4 and activation of GADD153 promoter.
RNAi and dominant negative expression studies revealed that
both BiP and PERK promote survival and drug-resistance of dor-
mant cells and that BiP upregulation prevents Bax activation.
Further, genetic experiments showed that activation of the
PERK-eIF2a pathway is important for the maintenance of dor-
mancy. We propose that stress-dependent activation of p38 that
results in BiP upregulation and PERK activation may represent a
novel growth arrest and survival mechanism that induces dor-
mancy and protects dormant tumor cells from stress-insults
such as chemotherapy.
doi:10.1016/j.ejcsup.2006.04.009
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Colorectal cancer is the second leading cause of cancer deaths in
western countries. Although inactivation of the APC and p53
tumor suppressor genes coupled with Kirsten-Ras oncogene acti-
vation contribute to colon carcinogenesis, simultaneous muta-
tion of these three genes is rare suggesting alternate genetic
pathways leading to colon tumorigenesis/progression. To iden-
tify novel genes that contribute to colon cancer development/
progression we ‘‘data-mined’’ genes aberrantly expressed in
colorectal cancer using SAGE and UniGene Cluster Expression
analysis and identified, a novel Scan domain-containing zinc fin-
ger protein (ZNF306) whose expression is elevated in colon can-
cer. RT-PCR analysis of resected colon cancers showed elevated
ZNF306 mRNA levels in two thirds of tumors compared with
paired adjacent non-malignant tissue. Stable expression of the
cloned ZNF 306 cDNA in HCT 116 colon cancer cells yielded
enhanced soft agar colony formation, anoikis resistance and
resistance to 5-flurouracil when compared with cells bearing
the empty vector. More importantly, orthotopic implantation of
ZNF306-overexpressing HCT 116 cells yielded large tumors in
100% of the mice compared with vector only-expressing cells
which produced smaller tumors with a lower penetrance (20%
of mice). Conversely, transduction of two independent colon
cancer cell lines with a-ZNF306 siRNA reduced mRNA levels,
diminished colony size and attenuated cell proliferation. Fur-
ther, in vivo delivery of neutral liposomal-encapsulated siRNA
targeting ZNF306 reduced orthotopic growth of HCT116-ZNF306
cells. Flag-tagged expressed ZNF306 was nuclear-localized and
since zinc finger-containing proteins recognize DNA site-specific
sequences, we hypothesized that ZNF306 is a transcription fac-
tor. Cyclic amplification and selection of targets (CAST-ing) using
a random oligonucleotide library identified the KRKGGGG nucle-
otide sequence as a putative DNA binding site. Expression profil-
ing studies revealed several candidate downstream targets of
ZNF306 including VEGF and integrin b4, implicated in angiogen-
esis and Ras/PI3-kinase signaling, respectively. Over-expression
of these two putative targets was confirmed by RT-PCR. Addi-
tionally, increased CD31 (endothelial cells) immunoreactivity in
the ZNF306-over-expressing orthotopic tumors indicated aug-
mented angiogenesis. Both genes contained ZNF306 binding
sites in their regulatory sequences and chromatin immunopre-
cipitation assays and EMSA, using an anti-ZNF306 antibody we
generated, demonstrated binding of the ZNF306 protein to its
recognition sequence (identified by CAST-ing) in the VEGF pro-
moter indicating this gene to be a direct target of ZNF306.
Immunohistochemistry employing the anti-ZNF306 antibody
showed increased ZNF306 protein in colon cancer tissues com-
pared with adjacent non-malignant mucosa. In conclusion, we
have discovered a novel zinc finger protein, ZNF306 that contrib-
utes to colon cancer progression in part by elevating VEGF and
integrin b4 expression. We propose that this gene product repre-
sents a key protein in an alternate genetic pathway leading to
colon cancer progression.
doi:10.1016/j.ejcsup.2006.04.010
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The urokinase-receptor (u-PAR) promotes the invasive and meta-
static phenotype and has been shown to be associated with early
relapse and poor prognosis in enumerous types of cancers. From
our and other studies we know that high u-PAR gene expression
in carcinoma cells is largely due to the transcriptional regulation
of the gene. We have characterized two cis-elements (152/135,
bound with an AP-2-like protein, Sp1, and Sp3; 190/171, bound
with AP-1-transcription factors) of the u-PAR promoter which are
decisive for diverse means of u-PAR-gene expression in highly
invasive colon cancer cells, among them being constitutive,
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